Search

Your search keyword '"G. Scagliotti"' showing total 122 results

Search Constraints

Start Over You searched for: Author "G. Scagliotti" Remove constraint Author: "G. Scagliotti"
122 results on '"G. Scagliotti"'

Search Results

51. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

52. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.

53. Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells.

54. A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.

55. ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme.

56. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.

57. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.

58. Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.

59. Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone.

60. Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations.

61. Clinical meta-analyses of targeted therapies in adenocarcinoma.

62. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology.

63. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

64. Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer.

65. Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer.

66. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.

67. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.

68. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.

69. Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases.

70. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

71. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.

72. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.

73. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

75. Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.

76. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.

77. New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS.

78. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.

80. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.

81. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.

82. Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy.

83. Lung cancer stage is an independent risk factor for surgical mortality.

84. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.

85. Multimodality approach to early-stage non-small cell lung cancer.

86. Optimizing chemotherapy for patients with advanced non-small cell lung cancer.

87. Proteasome inhibitors in lung cancer.

88. An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer.

89. Low dose CT in early lung cancer diagnosis: Prevalence data.

90. Rubella and measles seroprevalence among women of childbearing age, Argentina, 2002.

91. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.

92. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.

93. Varicella seroprevalence and molecular epidemiology of varicella-zoster virus in Argentina, 2002.

94. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

95. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

96. Adjuvant chemotherapy after complete resection for early stage NSCLC.

97. Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer.

98. Supportive care in patients with advanced non-small-cell lung cancer.

99. Targeted therapy in combination with gemcitabine in non-small cell lung cancer.

100. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.

Catalog

Books, media, physical & digital resources